| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Background: The overexpression of HER-2 (c-erbB2/Neu) in breast cancer is associated with poor prognosis, tumor recurrence and shortened survival. The administration of the trastuzumab significantly improves patients prognosis. However, in spite of these successful results, trastuzumab is effective only in 20-40% of cases. PI3K/Akt and Ras/MAPK signaling pathways are activated through HER-2 receptor and both play important role in tumor behavior. Methods: The study included 76 women with verified Her-2+ metastatic breast cancer (MBC) who were treated with trastuzumab based palliative chemotherapy. Immunohistochemistry was performed on formalin fixed, paraffin embedded tissue sections with antibodies against Akt-1, Akt-2, phospho(p)-Akt-Ser-473 and p-Akt-Thr-308, PTEN, S6K, p-S6K- Ser235/236, MAPK, p-MAPK-Thr202/Tyr204. Except PTEN, the cytoplasmatic and nuclear fractions were assessed separately. Results: Patients whose tumors showed high Akt-2 expression (> 80% positive cells) accompanied with nuc
- Background: The overexpression of HER-2 (c-erbB2/Neu) in breast cancer is associated with poor prognosis, tumor recurrence and shortened survival. The administration of the trastuzumab significantly improves patients prognosis. However, in spite of these successful results, trastuzumab is effective only in 20-40% of cases. PI3K/Akt and Ras/MAPK signaling pathways are activated through HER-2 receptor and both play important role in tumor behavior. Methods: The study included 76 women with verified Her-2+ metastatic breast cancer (MBC) who were treated with trastuzumab based palliative chemotherapy. Immunohistochemistry was performed on formalin fixed, paraffin embedded tissue sections with antibodies against Akt-1, Akt-2, phospho(p)-Akt-Ser-473 and p-Akt-Thr-308, PTEN, S6K, p-S6K- Ser235/236, MAPK, p-MAPK-Thr202/Tyr204. Except PTEN, the cytoplasmatic and nuclear fractions were assessed separately. Results: Patients whose tumors showed high Akt-2 expression (> 80% positive cells) accompanied with nuc (en)
- Background: The overexpression of HER-2 (c-erbB2/Neu) in breast cancer is associated with poor prognosis, tumor recurrence and shortened survival. The administration of the trastuzumab significantly improves patients prognosis. However, in spite of these successful results, trastuzumab is effective only in 20-40% of cases. PI3K/Akt and Ras/MAPK signaling pathways are activated through HER-2 receptor and both play important role in tumor behavior. Methods: The study included 76 women with verified Her-2+ metastatic breast cancer (MBC) who were treated with trastuzumab based palliative chemotherapy. Immunohistochemistry was performed on formalin fixed, paraffin embedded tissue sections with antibodies against Akt-1, Akt-2, phospho(p)-Akt-Ser-473 and p-Akt-Thr-308, PTEN, S6K, p-S6K- Ser235/236, MAPK, p-MAPK-Thr202/Tyr204. Except PTEN, the cytoplasmatic and nuclear fractions were assessed separately. Results: Patients whose tumors showed high Akt-2 expression (> 80% positive cells) accompanied with nuc (cs)
|
| Title
| - The impact of signaling pathways stimulated by HER2 receptor on prediction of clinical outcome in metastatic breast cancer patients treated with trastuzumab.
- The impact of signaling pathways stimulated by HER2 receptor on prediction of clinical outcome in metastatic breast cancer patients treated with trastuzumab. (en)
- Význam signálních drah stimulovaných HER2 receptorem v predikci odpovědi na léčbu trastuzumabem u pacientek s metastatickým karcinomem prsu. (cs)
|
| skos:prefLabel
| - The impact of signaling pathways stimulated by HER2 receptor on prediction of clinical outcome in metastatic breast cancer patients treated with trastuzumab.
- The impact of signaling pathways stimulated by HER2 receptor on prediction of clinical outcome in metastatic breast cancer patients treated with trastuzumab. (en)
- Význam signálních drah stimulovaných HER2 receptorem v predikci odpovědi na léčbu trastuzumabem u pacientek s metastatickým karcinomem prsu. (cs)
|
| skos:notation
| - RIV/00216224:14110/07:00028234!RIV09-MZ0-14110___
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/00216224:14110/07:00028234
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - breast cancer; trastuzumab; prognosis; prediction; HER-2/neu gene (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - Journal of Clinical Oncology
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Radová, Lenka
- Svoboda, Marek
- Vyzula, Rostislav
- Fabian, Pavel
- Nenutil, Rudolf
- Palácová, Markéta
- Grell, Peter
- Dziechciarkova, Marta
|
| issn
| |
| number of pages
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)